These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17722195)

  • 41. Adaptive two-stage designs in phase II clinical trials.
    Banerjee A; Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Admissible two-stage designs for phase II cancer clinical trials.
    Jung SH; Lee T; Kim K; George SL
    Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
    Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
    Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Paradigms for adaptive statistical information designs: practical experiences and strategies.
    Wang SJ; Hung HM; O'Neill R
    Stat Med; 2012 Nov; 31(25):3011-23. PubMed ID: 22927234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pregabalin. A new treatment for neuropathic pain].
    López-Trigo J; Sancho Rieger J
    Neurologia; 2006 Mar; 21(2):96-103. PubMed ID: 16525916
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adaptive designs for binary treatment responses in phase III clinical trials: controversies and progress.
    Biswas A
    Stat Methods Med Res; 2001 Oct; 10(5):353-64. PubMed ID: 11697227
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial.
    Irving G; Jensen M; Cramer M; Wu J; Chiang YK; Tark M; Wallace M
    Clin J Pain; 2009; 25(3):185-92. PubMed ID: 19333167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of adaptive allocation rules for group-sequential binary response clinical trials.
    Morgan CC; Stephen Coad D
    Stat Med; 2007 Apr; 26(9):1937-54. PubMed ID: 16981177
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.
    Retout S; Mentré F; Bruno R
    Stat Med; 2002 Sep; 21(18):2623-39. PubMed ID: 12228881
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pregabalin: new drug. Very similar to gabapentin.
    Prescrire Int; 2005 Dec; 14(80):203-6. PubMed ID: 16397976
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adaptive designs for dose-finding studies based on sigmoid Emax model.
    Dragalin V; Hsuan F; Padmanabhan SK
    J Biopharm Stat; 2007; 17(6):1051-70. PubMed ID: 18027216
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimal designs for estimating the interesting part of a dose-effect curve.
    Miller F; Guilbaud O; Dette H
    J Biopharm Stat; 2007; 17(6):1097-115. PubMed ID: 18027219
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pregabalin (Lyrica) and neuropathic pain syndromes].
    Jacquy J; Lossignol D; Sternon J
    Rev Med Brux; 2006; 27(5):445-50. PubMed ID: 17144644
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adaptive Dunnett tests for treatment selection.
    Koenig F; Brannath W; Bretz F; Posch M
    Stat Med; 2008 May; 27(10):1612-25. PubMed ID: 17876763
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An improved method of evaluating drug effect in a multiple dose clinical trial.
    Shen L
    Stat Med; 2001 Jul; 20(13):1913-29. PubMed ID: 11427949
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study.
    Baron R; Brunnmüller U; Brasser M; May M; Binder A
    Eur J Pain; 2008 Oct; 12(7):850-8. PubMed ID: 18242109
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adaptive clinical trials for new drug applications in Japan.
    Ando Y; Hirakawa A; Uyama Y
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):175-9. PubMed ID: 20961739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China.
    Guan Y; Ding X; Cheng Y; Fan D; Tan L; Wang Y; Zhao Z; Hong Z; Zhou D; Pan X; Chen S; Martin A; Tang H; Cui L
    Clin Ther; 2011 Feb; 33(2):159-66. PubMed ID: 21444113
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bayesian optimal adaptive designs for delayed-response dose-finding studies.
    Li W; Fu H
    J Biopharm Stat; 2011 Sep; 21(5):888-901. PubMed ID: 21830921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Models for event-driven data: longitudinal daily adverse event and dropout.
    Miller R; Ito K; Lalovic B
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):58S-62S. PubMed ID: 20881219
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.